On the other hand, the use of PI3K inhibitors in cohorts of breast cancer patients resulted in favorable PFS specifically for patients with PI3KCA mutation, thus showing that genetic alterations in PIK3CA are predictive markers of PI3K inhibitor benefit. The gene discussed is PIK3CB; the disease is breast carcinoma.